Blinklab Limited (AU:BB1) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
BlinkLab Limited has made significant progress towards obtaining FDA clearance for its autism diagnostic app, BlinkLab Dx 1. The company announced a positive outcome from its Pre-Submission meeting with the FDA, which confirmed the study design and data requirements needed for approval. A large-scale clinical study involving up to 1,000 children across multiple sites in the U.S. is underway, aiming for completion within 12-16 months.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
